Cy­to­Dyn fires em­bat­tled CEO as its grow­ing cho­rus of crit­ics gets loud­er

Among the many biotechs and phar­mas pitch­ing their cor­ner­stone drugs as po­ten­tial cures for Covid-19, few have earned as ig­no­min­ious a rep­u­ta­tion as Cy­to­Dyn. Fac­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER